



#3

PTO/SB/08 (2-92)

Sheet 1 of 2

Form PTO-1449

Docket Number 300622002610

Application Number 09/825,621

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Christopher REEVES et al.

Filing Date April 3, 2001

Group Art Unit ~~4652~~ 1625

Mailing Date April 5, 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10/1989	4,874,748	Katz et al.	514	29	
	2.	11/1991	5,063,155	Cox et al.	435	76	
	3.	03/1992	5,098,837	Beckmann et al.	435	172.3	
	4.	09/1992	5,149,639	Katz et al.	435	76	
	5.	02/1993	5,189,042	Goulet et al.	514	291	
Av	6.	09/1997	5,672,491	Khosla et al.	435	148	
Av	7.	01/1998	5,712,146	Khosla et al.	435	252.35	
	8.	10/1998	5,824,513	Katz et al.	435	76	
Av	9.	11/1998	5,830,750	Khosla et al.	435	252.35	
	10.	12/1998	5,843,718	Khosla et al.	435	69.1	
I	11.	10/1999	5,962,290	Khosla et al.	435	183	
	12.	02/2000	6,022,731	Khosla et al.	435	252.35	
Av	13.	06/2000	6,077,696	Khosla et al.	435	135	
	14.	11/2000	6,150,513	Wu	536	23.2	

RECEIVED

APR 17 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
Av	15.	07/05/1989	EP 0323042A	EPO	—	—	
Av	16.	02/28/1990	EP 0356399A	EPO	—	—	
Av	17.	01/02/1992	EP 0463690A	EPO	—	—	
	18.	07/1993	WO 93/13663	WIPO	—	—	
	19.	03/1995	WO 95/08548	WIPO	—	—	
	20.	12/1996	WO 96/40968	WIPO	—	—	
	21.	01/1997	WO 97/02358	WIPO	—	—	
	22.	06/1998	WO 98/27203	WIPO	—	—	

EXAMINER:

Amelia Tovar

DATE CONSIDERED:

4-4-2003

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 300622002610	Application Number 09/825,621
	Applicant Christopher REEVES et al.	
	Filing Date April 3, 2001	Group Art Unit 1652
	Mailing Date April 5, 2002	

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

23	11/1998	WO 98/49315	WIPO
24	04/2000	WO 00/20601	WIPO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	25.	Caffrey et al., 1992, FEBS Letters 304: 205
Au	26.	Chen T.S. et al. (1992). "Microbial Transformation of Immunosuppressive Compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 9500520 by Actinomycete sp. ATCC 53828," <i>J Antibiot</i> 45(4):577-580.
Au	27.	Dumont F.J. et al. (1992). "The Immunosuppressive and Toxic Effects of FK-506 Are Mechanically Related: Pharmacology of a Novel Antagonist of FK-506 and Rapamycin," <i>J of Exp Medicine</i> 176(3):751-760.
	28.	Fu et al., 1994, <i>Biochemistry</i> 33: 9321-9326
Au	29.	Iwasaki et al., (1993) <i>Drug Metabolism and Disposition</i> 21:971-977
Au	30.	Iwasaki et al., (1995) <i>Drug Metabolism and Disposition</i> 23:28-34
Au	31.	Kawai et al., (1993) <i>FEBS Letters</i> 316(2):107-113
Au	32.	Khosla C. (1997). "Harnessing the Biosynthetic Potential of Modular Polyketide Synthases," <i>Chemical Reviews</i> 97(7):2577-2590.
	33.	McDaniel et al., 1993, Science 262: 1546-1550
Au	34.	Motamedi et al., (1996) <i>J. Bacteriol.</i> 178:5243-5248
Au	35.	Motamedi et al., (1997) <i>Eur. J. Biochem.</i> 244:78-80
Au	36.	Motamedi and Shafiee, (1998) <i>Eur. J. Biochem.</i> 256:528
Au	37.	Reynolds K.A. et al. (1997). "Rapamycin, FK506, and Ascomycin-related Compounds," <i>Drugs Pharm Sci</i> 82:497-520.
	38.	Rohr, 1995, Angew. Chem. Int. Ed. Engl. 34(8): 881-888-
Au	39.	Shafiee A. et al. (1993). "Enzymatic synthesis and Immunosuppressive Activity of Novel Desmethylated Immunomycins (Ascomycins)," <i>J Antibiot</i> 46(9):1397-1405.
Au	40.	Stassi D.L. et al. (1998). "Ethyl-substituted Erythromycin Derivatives Produced by Directed Metabolic Engineering," <i>Proc Natl Acad Sci USA</i> 95 (13):7305-7309.
Au	41.	Wu et al., (2000) <i>Gene</i> 251:81-90

EXAMINER: Amelia Owens

DATE CONSIDERED: 4-4-2003

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 300622002610

Application Number 09/825,621

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Christopher REEVES et al.

Filing Date April 3, 2001

Group Art Unit 1652/1625

Mailing Date August 30, 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10/1999	5,968,921	Gold	514	183	
	2.	04/2001	6,210,974	Gold	436	501	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	3.	Gold et al., (1995) Journal of Neuroscience 15:7509-7516
	4.	Gold et al., (1999) J. Pharm. Exp. Ther. 289(3):1202-1210
	5.	Harrison's Principles of Internal Medicine, 14th Edition, 1998, McGraw Hill, Chapters 14,20,21,64-67
	6.	Lyons et al., (1994) Proc. Natl. Acad. Sci. USA 91:3191-3195
	7.	Shiraga et al., (1994) Biochem. Pharmacol. 47:727-735
	8.	Steiner et al., (1997) Proc. Natl. Acad. Sci. USA 94:2019-2024
	9.	Vincent et al., (1992) Arch. Biochem. Biophys. 294:454-460

COPY OF PAPERS
ORIGINALLY FILED

EXAMINER:

Amelia Owens

DATE CONSIDERED:

4-4-03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

SEP 11 2002

TECH CENTER 1600/2000

